Scientists at UT Health San Antonio have found a promising way to stop glioblastoma—the deadliest type of brain cancer—from ...

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

Glioblastoma, one of the most aggressive and lethal brain cancers, has a five-year survival rate of only 6.9%, according to the National Brain Tumor Society. While the relationship between ...

Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with ...

Former Utah congresswoman Mia Love will lie in state at the Utah State Capitol, allowing the public to pay their respects to ...

Researchers at The University of Texas Health Science Center at San Antonio have discovered a way to delay or even block ...

What is glioblastoma, the aggressive brain cancer that killed Mia Love at 49? - The death of former U.S. Rep. Mia Love has ...

Researchers at Yale Cancer Center have made a breakthrough finding that could lead to a therapies for glioblastoma and other ...

Research led by The University of Texas Health Science Center at San Antonio discovers a means of slowing or even blocking recurrence of glioblastoma, the deadliest form of brain cancer.

After 25 years at the Tampa Tribune, where he was a reporter and editorial writer, he became a hearing officer overseeing child support enforcement.